These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18546628)

  • 1. Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients.
    Murph MM; Smith DL; Hennessy B; Lu Y; Joy C; Coombes KR; Mills GB
    Adv Exp Med Biol; 2008; 622():183-95. PubMed ID: 18546628
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting PI3K-AKT pathway for cancer therapy.
    Lu Y; Wang H; Mills GB
    Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Getting the details right: gene signatures for cancer therapy.
    Master SR
    Clin Chem; 2010 Sep; 56(9):1378-80. PubMed ID: 20592045
    [No Abstract]   [Full Text] [Related]  

  • 4. Proteomics and biomarkers in clinical trials for drug development.
    Lee JM; Han JJ; Altwerger G; Kohn EC
    J Proteomics; 2011 Nov; 74(12):2632-41. PubMed ID: 21570499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
    Maira SM; Furet P; Stauffer F
    Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
    Lackner MR
    Expert Rev Mol Diagn; 2010 Jan; 10(1):75-87. PubMed ID: 20014924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PI3K-AKT-mTOR pathway: Description, therapeutic development, resistance, predictive/prognostic biomarkers and therapeutic applications for cancer].
    Brotelle T; Bay JO
    Bull Cancer; 2016 Jan; 103(1):18-29. PubMed ID: 26582734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
    Wang X; Ding J; Meng LH
    Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse phase protein microarrays advance to use in clinical trials.
    Mueller C; Liotta LA; Espina V
    Mol Oncol; 2010 Dec; 4(6):461-81. PubMed ID: 20974554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New phosphatidylinositol 3-kinase inhibitors for cancer.
    Bowles DW; Jimeno A
    Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
    Findeisen P; Neumaier M
    Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving the goals of effective, safe, and individualized cancer care.
    Roberts SA; Karnes EK; Allen JD; Benner JS; Sigal EV; McClellan M
    Clin Cancer Res; 2011 Nov; 17(21):6632-3. PubMed ID: 22046023
    [No Abstract]   [Full Text] [Related]  

  • 16. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene of the month: PIK3CA.
    Lai K; Killingsworth MC; Lee CS
    J Clin Pathol; 2015 Apr; 68(4):253-7. PubMed ID: 25688137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
    Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.